vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $205.4M, roughly 1.3× COLLEGIUM PHARMACEUTICAL, INC). WESBANCO INC runs the higher net margin — 34.5% vs 8.3%, a 26.2% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs 19.1%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
COLL vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $257.2M |
| Net Profit | $17.0M | $88.6M |
| Gross Margin | 62.5% | — |
| Operating Margin | 29.6% | — |
| Net Margin | 8.3% | 34.5% |
| Revenue YoY | 12.9% | — |
| Net Profit YoY | 35.3% | 54.4% |
| EPS (diluted) | $0.48 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $205.4M | $265.6M | ||
| Q3 25 | $209.4M | $261.6M | ||
| Q2 25 | $188.0M | $260.7M | ||
| Q1 25 | $177.8M | $193.2M | ||
| Q4 24 | $181.9M | $162.9M | ||
| Q3 24 | $159.3M | $150.8M | ||
| Q2 24 | $145.3M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $17.0M | $91.1M | ||
| Q3 25 | $31.5M | $83.6M | ||
| Q2 25 | $12.0M | $57.4M | ||
| Q1 25 | $2.4M | $-9.0M | ||
| Q4 24 | $12.5M | $49.6M | ||
| Q3 24 | $9.3M | $37.3M | ||
| Q2 24 | $19.6M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 62.5% | — | ||
| Q3 25 | 61.7% | — | ||
| Q2 25 | 57.7% | — | ||
| Q1 25 | 54.8% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 62.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 29.6% | 43.2% | ||
| Q3 25 | 29.7% | 39.5% | ||
| Q2 25 | 18.7% | 27.2% | ||
| Q1 25 | 12.2% | -5.0% | ||
| Q4 24 | 20.9% | 38.0% | ||
| Q3 24 | 21.9% | 29.7% | ||
| Q2 24 | 32.7% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | 8.3% | 34.3% | ||
| Q3 25 | 15.0% | 31.9% | ||
| Q2 25 | 6.4% | 22.0% | ||
| Q1 25 | 1.4% | -4.7% | ||
| Q4 24 | 6.9% | 30.5% | ||
| Q3 24 | 5.9% | 24.7% | ||
| Q2 24 | 13.5% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.48 | $0.97 | ||
| Q3 25 | $0.84 | $0.84 | ||
| Q2 25 | $0.34 | $0.57 | ||
| Q1 25 | $0.07 | $-0.15 | ||
| Q4 24 | $0.36 | $0.72 | ||
| Q3 24 | $0.27 | $0.54 | ||
| Q2 24 | $0.52 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $4.1B |
| Total Assets | $1.7B | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $386.7M | $956.1M | ||
| Q3 25 | $285.9M | $1.0B | ||
| Q2 25 | $222.2M | $1.2B | ||
| Q1 25 | $197.8M | $1.1B | ||
| Q4 24 | $162.8M | $568.1M | ||
| Q3 24 | $120.0M | $620.9M | ||
| Q2 24 | $271.6M | $486.8M |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $301.7M | $4.0B | ||
| Q3 25 | $274.8M | $4.1B | ||
| Q2 25 | $232.2M | $3.8B | ||
| Q1 25 | $234.4M | $3.8B | ||
| Q4 24 | $228.8M | $2.8B | ||
| Q3 24 | $234.3M | $2.8B | ||
| Q2 24 | $216.6M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $1.7B | $27.7B | ||
| Q3 25 | $1.6B | $27.5B | ||
| Q2 25 | $1.6B | $27.6B | ||
| Q1 25 | $1.6B | $27.4B | ||
| Q4 24 | $1.7B | $18.7B | ||
| Q3 24 | $1.6B | $18.5B | ||
| Q2 24 | $1.1B | $18.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | — |
| Free Cash FlowOCF − Capex | $122.4M | — |
| FCF MarginFCF / Revenue | 59.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $123.0M | $290.4M | ||
| Q3 25 | $78.4M | $116.9M | ||
| Q2 25 | $72.4M | $105.0M | ||
| Q1 25 | $55.4M | $-26.4M | ||
| Q4 24 | $84.6M | $211.0M | ||
| Q3 24 | $-9.0M | $60.7M | ||
| Q2 24 | $67.4M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $122.4M | $280.0M | ||
| Q3 25 | $78.3M | $114.9M | ||
| Q2 25 | $72.4M | $98.3M | ||
| Q1 25 | $54.6M | $-30.7M | ||
| Q4 24 | $84.1M | $200.7M | ||
| Q3 24 | $-9.2M | $56.9M | ||
| Q2 24 | $67.1M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | 59.6% | 105.4% | ||
| Q3 25 | 37.4% | 43.9% | ||
| Q2 25 | 38.5% | 37.7% | ||
| Q1 25 | 30.7% | -15.9% | ||
| Q4 24 | 46.2% | 123.2% | ||
| Q3 24 | -5.8% | 37.7% | ||
| Q2 24 | 46.2% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 3.9% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | 0.3% | 6.3% | ||
| Q3 24 | 0.2% | 2.5% | ||
| Q2 24 | 0.2% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 7.25× | 3.19× | ||
| Q3 25 | 2.49× | 1.40× | ||
| Q2 25 | 6.05× | 1.83× | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | 4.25× | ||
| Q3 24 | -0.96× | 1.63× | ||
| Q2 24 | 3.44× | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COLL
Segment breakdown not available.
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
